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Abstract Chronic obstructive pulmonary disease (COPD) is a respiratory condition characterized by progressive 
decline in lung function. It imposes a considerable burden on patients, healthcare services and society that is likely to 
increase in the future. It is, therefore, important to ensure that this disease is managed as effectively as possible. 
In many therapeutic areas, management guidelines have been developed in an attempt to ensure that physicians are aware 
of optimal disease management and cost-effective use of healthcare resources. Such guidelines are usually prepared by 
consensus among clinical experts or following a systematic review of the evidence. However, there are a number of 
barriers to the implementation of treatment guidelines, including the sheer weight of guidelines in all therapeutic areas, a 
focus on scientific knowledge rather than on clinical practice, lack of trust in the recommendations, practical considerations 
(e.g. time, resources, budget) and failure to include the perspective of patients.The management guidelines most likely to 
be implemented are those that are quick and easy to use, relevant to the user’s practice and from a credible source. 
In COPD, over 40 guidelines have been developed, mainly by local respiratory societies as a result of local expert 
consensus.The guidelines developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) are evidence- 
based and have the backing of international experts. Local implementation plans have been developed to help ensure that 
GOLD recommendations are implemented in practice. In all COPD guidelines, however; lung function measures feature 
prominently, with limited reference to outcome measures of interest to patients and healthcare payers (e.g. frequency of 
exacerbations requiring hospitalization). Low expectations among physicians and patients may also impair implementation. 
In conclusion, guidelines may improve the management of COPD, but the main challenge is to ensure implementation. 
02002 Elsevier Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
respiratory condition characterized by progressive decline 
in lung function, usually as a response to inhalation of 
noxious substances such as tobacco smoke. Patients suffer 
symptoms of dyspnoea and cough, with impairment in 
ability to carry out daily activities and progressive decline 
in quality of life. Patients with COPD may experience 
frequent and severe exacerbations, resulting in costly 
hospitalizations; COPD is also a leading cause of mortality 
globally. Clearly, the burden of COPD is considerable for 
patients, healthcare services and society - and is expected 
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to increase in the short and medium term as the result of 
previous smoking behaviour (1,2). It is, therefore, 
important to ensure that this disease is managed as 
effectively as possible, in order to limit patient suffering 
and to make optimal use of healthcare resources. 
Management guidelines are increasingly used to 
communicate best practice, to try to ensure that all 
patients receive optimal management.Yet the availability 
of guidelines does not guarantee improvement in disease 
management and cost-effective use of healthcare 
resources. The method of developing guidelines, their 
content and the way that they are communicated will all 
influence implementation. These issues are examined in 
this paper, and the lessons learnt are considered in 
relation to guidelines for COPD management, with 
particular reference to the guidelines developed by the 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), a collaboration between the World Health 
Organisation and the U.S. National Heart, Lung and 
Blood Institute (3). 
AIMS AND PERSPECTIVES OF 
MANAGEMENT GUIDELINES 
Management guidelines aim to summarize best practice 
and recommend appropriate management strategies for 
all categories of patients suffering from the disease in 
question.They are usually written by clinical experts, for 
clinicians. Physicians use management guidelines as a 
means of assessing their current practice and as an aid to 
improving health outcomes - including those of 
importance to patients. Guidelines may also be used by 
physicians as an educational tool with patients during 
consultations. Healthcare decision makers may use 
management guidelines to raise awareness of a disease 
and to set optimal treatment standards. If the outcome 
of different management approaches is also considered 
in relation to its impact on the use of healthcare 
resources, healthcare payers may use management 
guidelines to allocate resources efficiently. The 
perspectives of other groups (e.g. society, employer, 
school) may also be included in management guidelines. 
THE DEVELOPMENT OF 
MANAGEMENT GUIDELINES 
The process of developing recommendations for 
management guidelines may be driven by expert 
consensus or based on published evidence on disease 
management. There are important differences in these 
two approaches to development. 
Expert consensus 
Recommendations for management guidelines may arise 
from discussion among experts, particularly when 
evidence available to support treatments is relatively 
limited, though it may be difficult for those outside the 
development process to see how the recommendations 
were reached. A more explicit approach to the develop- 
ment of guidelines by experts is the inclusion of a formal 
consensus process, with defined decision-making rules. 
Evidence-based 
Management guidelines may be developed using an 
evidence-based approach. A systematic and complete 
review of the available literature is conducted, including 
evidence from many different sources such as 
randomized controlled trials, epidemiological databases, 
observational studies and expert opinion.To help decide 
on the quality of the evidence associated with a 
particular treatment, a number of important considera- 
tions are taken into account (Table I). 
To aid the review process, the developers of guidelines 
may use hierarchies of evidence. For example, the 
National Institute of Clinical Excellence (NICE) in the 
U.K. refers to four levels of evidence when considering 
treatments for recommendation (Table 2) (4). Evidence 
from at least one well-conducted, randomized controlled 
trial is considered to represent the best available 
evidence, being placed at level I at the top of the 
hierarchy. Although the information provided by studies 
placed at the top of the hierarchy is considered to be 
more reliable and valid than the information placed at 
other levels (and therefore given greater weighting), 
evidence-based recommendations reflect the 
assimilation of all available data. NICE uses five levels of 
treatment recommendation that relate explicitly to the 
body of evidence considered during the review process 
(Table 2) (4). 
PRESENTATION AND 
COMMUNICATION OF GUIDELINES 
In addition to presentation of the body of evidence and 
recommendations, treatment guidelines may include an 
executive summary of the key points.A short guide for 
physicians may be provided, which may be in the form of 
a single page summary or a laminated card. Simple flow 
charts or algorithms, and checklists for common multi- 
step procedures, are also useful ways of presenting the 
guidelines to physicians. To assist in education during 
consultations, guides for patients are useful, which may 
be in the form of tear-off sheets. Posters or wall charts 
can help in patient education, and also remind clinicians 
about the guidelines. 
BARRIERS TO IMPLEMENTATION OF 
MANAGEMENT GUIDELINES 
It is, of course, important to remember that implemen- 
tation of guidelines does not necessarily follow from the 
development of guidelines that have useful content, even 
if they are clearly communicated to interested parties. 
There are a number of potential barriers to the acceptance 
and use of guidelines in clinical practice (Table 3). 
The sheer volume of clinical practice guidelines 
developed for every therapeutic area over the past 
decade has become overwhelming (5) and physicians 
have little time or opportunity to consider their 
recommendations in detail. Furthermore, physicians may 
also be faced with directives on patient care from 
healthcare payers. Scant attention may be paid to new 
guidelines if those already in circulation are widely used. 
Guidelines may not be implemented if physicians have 
no sense of ownership. Guidelines developed by expert 
consensus are implicit, making it difficult for physicians to 
see how recommendations were reached, which may 
lead to the recommendations being distrusted. Evidence- 
based guidelines are generally more acceptable than 
those produced by expert consensus because of the 
greater transparency in scientific and clinical evidence 
used (5). Whatever the approach to development, 
physicians are unlikely to accept recommendations that 
they perceive as threatening to their professional 
judgement, sense of competence or autonomy (6). They 
are also unlikely to implement recommendations if these 
are in conflict with their personal experience or if they 
consider the evidence base to be weak. 
Guidelines are often written with the purpose of 
disseminating the latest thinking and scientific 
knowledge in a therapeutic area, rather than being 
targeted to clinical practice. Many guidelines do not 
provide practical implementation plans for use at the 
local level.They may be written in a complicated way, 
with too much text, and insufficient tables or figures. 
There may be practical barriers to implementation of 
the recommendations. Physicians may not have the time 
or resources available to prescribe recommended 
treatments. Furthermore, physicians may face constraints 
on healthcare budgets that make it difficult for them to 
provide recommended treatments. They may also 
choose to ignore guidelines because of financial 
incentives acting against the recommendations, and 
because of fear of malpractice litigation. 
Where physicians do accept and implement guidelines, 
patient attitudes to interventions may provide an 
additional challenge to their implementation in practice. 
Recommendations can only improve health outcomes if 
the patient is willing or able to accept the management 
advice given.This underlines the importance of including 
the patient perspective when management guidelines are 
developed. Furthermore, it should be remembered that 
studies to examine the effect of practice guidelines have 
usually examined changes in the behaviour of physicians, 
not changes in patient outcomes (6). 
INCREASING THE IMPACT OF 
MANAGEMENT GUIDELINES 
Research among focus groups consisting of primary care 
physicians, academic physicians and nurses has shown 
that the guidelines that are most likely to be 
implemented are those that are: 
?? quick and easy to use 
?? relevant to the user’s practice 
?? from a credible source (for example, expert panels 
assembled by federal agencies in the U.S.A.). 
The validity of guidelines is related to the 
composition of the development panel, the process 
used, the identification and synthesis of evidence, and 
the method of guideline construction. Including the 
perspectives of all relevant target users (patients, 
physicians, healthcare decision-makers) should help to 
increase the relevance of recommendations. It is also 
important to ensure that the measures of treatment 
success are appropriate (7) and take into account these 
different perspectives. 
Recommendations should take into account practical 
considerations. Guideline developers need to be realistic 
about what can be achieved during an average patient 
consultation, and provide guidelines in a format that is 
applicable to the organization of patient care. In primary 
care, this may include specific recommendations for the 
initial evaluation of patients and subsequent 
consultations. In designing and implementing program- 
mes to change practice, a number of questions should be 
considered: 
?? is the chosen intervention appropriate for the desired 
change in practice? 
?? do physicians support the proposed changes? 
?? how will the intervention be perceived - as a threat or 
a help? 
Although the development of appropriate 
recommendations may increase the likely impact of 
management guidelines, physicians may also need 
incentives to change their therapeutic behaviour. A 
number of methods have been identified to help change 
physician practices (Table4), though these are more 
effective when more than one approach is used (6). 
However, it should also be remembered that education is 
only likely to increase the implementation of guidelines 
when shortcomings in existing levels of care are due to 
lack of knowledge, and few physicians will respond to 
financial incentives if they feel that the health of their 
patients will be compromised. 
MANAGEMENT GUIDELINES FOR 
COPD 
So having considered the various issues around the 
development and implementation of management 
guidelines in general, how does this relate to the 
situation with COPD? Possibly in recognition of the 
growing burden imposed by COPD, there is now a 
plethora of more than 40 guidelines available for the 
management of this debilitating disease.The majority of 
these guidelines were developed by national and 
international respiratory disease societies, such as the 
British Thoracic Society (BTS) (8), and the American 
Thoracic Society (ATS) (9). Most do not state their 
intended audience, while the methodology used in 
guideline development, and the rigor of the process 
adopted, vary considerably across these guidelines. 
Almost all of the current COPD guidelines were 
developed by expert consensus. Consequently, few of the 
guidelines have international influence. In contrast, the 
GOLD guidelines (3) were developed by a systematic 
review of evidence and recommendations. These 
guidelines may, therefore, have wider application, so they 
will be considered in more detail. 
THE GOLD GUIDELINES FOR COPD 
The GOLD guidelines were developed by an international 
panel of experts using a hierarchy of evidence to review 
the information supporting alternative treatments for 
COPD (Table 5). A large body of data from randomized 
controlled trials was considered to provide the best 
available evidence (Evidence A), with consensus based on 
clinical experience or knowledge placed at the bottom of 
the hierarchy (Evidence D). These labels accompany 
recommendations in the GOLD guidelines. For example, 
recommendations associated with Evidence A include 
smoking cessation to reduce risk factors, and the use of 
bronchodilators for the symptomatic management in 
COPD (3).This approach to reviewing the evidence is very 
similar to the NICE approach (Table I). However, unlike 
the NICE approach, the link between levels of evidence 
and levels of recommendation in the GOLD guidelines is 
undefined. The strength of a recommendation reflects 
both the evidence available to support a therapy, and the 
importance of that recommendation in the expert opinion 
of the GOLD committee. 
The GOLD report (3) is implementation-orientated, 
covering diagnosis, management and prevention of 
COPD, using outcomes that can be evaluated. Outcomes 
in COPD considered important by GOLD, and evaluated 




use of rescue medications 
quality of life and impact on health status 
frequency and severity of exacerbations 
use of healthcare resources (physician visits, 
emergency department use, hospitalizations). 
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The report includes an introduction, overview on the 
definition and classification of COPD, summary of the 
burden of the disease, review of the risk factors for 
development and the pathogenesis, pathology and 
pathophysiology of COPD, evidence on management 
approaches and suggestions for future research. 
Once guidelines have been disseminated, the next 
challenge is to make sure that they are updated in a 
timely fashion. GOLD has taken a unique approach to 
achieving this objective. This has entailed developing 
methods to track and evaluate research on COPD and 
to assess its implications for management recom- 
mendations. To achieve this, a science-based committee 
of GOLD has been formed and the task of reviewing all 
English language papers relating to COPD started. Any 
information that could confirm or alter a GOLD 
recommendation is identified and the recommendation 
strengthened or modified accordingly. The plan is to 
update the GOLD recommendations annually so that the 
guidelines are a ‘living’ document. 
A dissemination committee has also been formed, as 
part of the GOLD programme, to develop materials to 
communicate the guidelines.These include many of the 
elements (e.g. summaries, patient education materials) 
previously identified as contributing to the successful 
communication of guidelines. The materials can be 
adapted to the infrastructure of the local environment 
and culture in each country. Over 40 countries have a 
launch leader to steer the development of local 
implementation plans, engaging local opinion leaders. 
Support and endorsement has been gained from allied 
healthcare professionals and relevant local organizations. 
THE IMPACT OF COPD GUIDELINES 
IN PRACTICE 
Treatment guidelines for COPD have gone some way 
towards international standardization of diagnosis and 
management, and have improved patient care (5). 
However, many patients with COPD continue to be 
undiagnosed or undertreated (3) suggesting that guide- 
lines are not being fully implemented. 
Guidelines such as those produced by the BTS,ATS, 
European Respiratory Society (ERS) (IO) and GOLD 
recommend treatment for patient populations at particular 
disease stages.These are defined by lung function criteria, 
such as the ratio between forced expiratory volume in I 
second (FEV,) and forced vital capacity (FVC).Although 
these criteria provide a useful benchmark against which 
disease progression may be monitored, they are difficult 
to use in practice as they do not relate directly to the 
signs and symptoms seen by physicians when patients 
present. Furthermore, there may be limited access to 
spirometers, limited ability to use the equipment and 
limited ability to interpret the findings. The difficulty 
associated with implementing guidelines linked to spiro- 
metric measurements was highlighted in a descriptive 
study of care in I4 practices in the Netherlands, which 
used patient reports to assess compliance with 
guidelines covering asthma and COPD, over a l-year 
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period (I I). Despite guideline recommendations, two- 
thirds (67%) of patients did not have their lung function 
assessed with spirometry, due to practical barriers such 
as time constraints and restricted access to equipment. 
The impact of COPD guidelines may also be limited by 
the outcomes used to assess treatment recommen- 
dations. When making treatment decisions, physicians 
tend to be more concerned with improving patient 
health outcomes (such as quality of life, or exacerbation 
rates) than lung function criteria. However, the majority 
of guideline recommendations are based on efficacy as 
defined by lung function criteria. 
Another factor that limits the impact of COPD 
guidelines is the acceptance of relatively poor levels of 
disease management by patients and physicians, who 
tend to overestimate the degree of management 
achieved, and underestimate the efficacy potential of 
interventions (I 2). Physicians who already feel satisfied 
with patient health outcomes have little incentive to 
consult treatment guidelines, while patients who accept 
current levels of care are unlikely to seek alternative 
therapies. In addition, chronic diseases are associated 
with low levels of patient adherence with recommended 
treatments (I 3), whether intentional (e.g. refusing to take 
medication because of the fear of side-effects) or 
unintentional (e.g. occasionally forgetting to take doses in 
complex treatment regimens).This may limit the extent 
to which COPD treatment recommendations can 
improve patient health outcomes. 
CONCLUSIONS 
It is clear that guidelines are now a fact of life, and will be 
used by many different groups - patients, providers, 
lawyers and healthcare decision-makers, as well as 
physicians. Though the development of guidelines is 
difficult, much is known about the most successful ways to 
disseminate the information. However, the big challenge 
remains implementation with consequent changes in 
behaviour, so that the burden of COPD can be reduced. 
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